Bg pattern

MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Mepsevii 2mg/ml concentrate for solution for infusion

vestronidase alfa

This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of this leaflet includes information on how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet (see section 4).

Contents of the pack

  1. What is Mepsevii and what is it used for
  2. What you need to know before you receive Mepsevii
  3. How Mepsevii is administered
  4. Possible side effects
  5. Storage of Mepsevii
  6. Contents of the pack and further information

1. What is Mepsevii and what is it used for

What is Mepsevii

Mepsevii contains a recombinant human enzyme called vestronidase alfa. This belongs to a group of medicines called "enzyme replacement therapies". It is given to adults and children of all ages with MPS VII to treat the non-neurological manifestations of the disease (mucopolysaccharidosis VII, also known as Sly syndrome).

What is MPS VII

MPS VII is a genetic inherited disease in which the body does not produce enough of an enzyme called beta-glucuronidase.

  • This enzyme breaks down mucopolysaccharides, which are a type of sugar.
  • Mucopolysaccharides are made by the body and help form bones, cartilage, skin, and tendons.
  • These sugars are constantly being recycled: new ones are created and old ones are broken down.
  • If there is not enough beta-glucuronidase, some of these sugars build up in cells, causing damage to the body.

How Mepsevii works

This medicine replaces beta-glucuronidase, helping to break down the sugars that build up in the tissues of people with MPS VII, preventing them from accumulating and causing symptoms of the disease.

  • Treatment may improve some signs and symptoms of the disease, such as walking problems and fatigue.

If treatment is started in early childhood, it may slow down the progression of the disease and reduce permanent damage.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you receive Mepsevii

Do not receive Mepsevii

  • if you are allergic to vestronidase alfa or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor before receiving Mepsevii.

The effects of treatment with vestronidase alfa will be evaluated periodically, and if no clear benefits are seen (including stabilization of clinical manifestations of the disease), discontinuation of treatment will be considered. Stopping treatment may cause significant worsening of the patient's clinical condition.

You should know that administration of vestronidase alfa does not correct irreversible complications of the disease (e.g., bone deformities).

Examine the side effects

  • You may experience a reaction to the administration of the drug known as "infusion reaction". This includes any side effect that occurs during infusion or the day after, including an allergic reaction (see section 4 "Possible side effects"). If you experience an infusion reaction, tell your doctor immediately.
  • If you experience an allergic reaction during infusion, your doctor may slow down or stop the infusion. Your doctor may also give you other medicines to treat the allergic reaction, such as an antihistamine, a corticosteroid, or an antipyretic (a medicine that lowers fever).

Other symptoms you should examine

  • If you experience neck or back pain, numbness in your arms or legs, or loss of control of sphincters, tell your doctor immediately.These symptoms could be signs of a disease caused by spinal cord compression.

Other medicines and Mepsevii

Tell your doctor if you are using, have recently used, or might use any other medicines.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.

Unless absolutely necessary, Mepsevii will not be given to you if you are pregnant. Discuss with your doctor if the benefits of Mepsevii outweigh the potential risks to the unborn baby, as there is no experience with the use of Mepsevii during pregnancy.

It is not known if Mepsevii passes into breast milk, but it is not expected to pass into your baby. Discuss with your doctor if the benefits of Mepsevii during breastfeeding outweigh the potential risks to the baby.

Driving and using machines

Mepsevii is unlikely to affect your ability to drive or use machines.

Mepsevii contains sodium

This medicine contains 17.8 mg of sodium (the main component of cooking/table salt) per 5 ml vial and is administered with a 9 mg/ml sodium chloride solution as a diluent. Therefore, each vial is equivalent to 1.8% of the maximum recommended daily sodium intake for an adult. Keep this in mind if you are on a low-sodium diet.

3. How Mepsevii is administered

Your doctor will start and monitor treatment with Mepsevii.

  • Your doctor or nurse will give you Mepsevii into a vein through infusion (drip).
  • This medicine must be diluted before administration.
  • Your doctor may also give you other medicines to treat possible allergic reactions, such as an antihistamine, a corticosteroid, or an antipyretic (a medicine that lowers fever).

Dose

The dose you receive will depend on your weight.

  • The recommended dose is 4 mg per kilogram of body weight.
  • This dose is given every two weeks through intravenous infusion.
  • Each infusion will be given over about 4 hours.

If you receive more Mepsevii than you should

Administration of Mepsevii will be supervised and monitored by your doctor so that the dose is correct and measures can be taken if necessary.

If you have any further questions on the use of this medicine, ask your doctor.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Side effects were mainly seen while patients were receiving the medicine or during the day after (reactions associated with infusion).

If you experience any reaction like this, contact your doctor immediatelyas you may need urgent treatment.

Very common side effects(affect more than 1 in 10 people):

  • Severe allergic reaction (anaphylactoid reaction) – Symptoms of a severe allergic reaction include, among others, shortness of breath, wheezing, difficulty breathing, and swelling of the face and tongue. Your doctor may give you other medicines to treat the allergic reaction, such as an antihistamine, a corticosteroid, or an antipyretic (a medicine that lowers fever).
  • Hives
  • Rash
  • Swelling at the infusion site, including fluid leaking into the tissues surrounding the vein (infusion site swelling or extravasation).

Common side effects(may affect up to 1 in 10 people):

  • Itching of the skin (pruritus)
  • Loose stools (diarrhea)
  • Fever with involuntary muscle contractions of the face or limbs (febrile convulsion)

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Mepsevii

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date ("EXP") stated on the carton. The expiry date is the last day of the month stated.

Unopened vials:

  • Store in a refrigerator (between 2°C and 8°C).
  • Do not freeze.
  • Store in the original package to protect from light.
  • Do not use this medicine if you notice particles in it.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and further information

What Mepsevii contains

  • The active substance is vestronidase alfa. Each ml of concentrate contains 2 mg of vestronidase alfa. Each 5 ml vial of concentrate contains 10 mg of vestronidase alfa.
  • The other ingredients are: sodium dihydrogen phosphate dihydrate, sodium chloride, histidine, polysorbate 20, and water for injections (regarding sodium, see section 2 "Mepsevii contains sodium").

Appearance of Mepsevii and pack contents

Mepsevii is provided as a concentrate for solution for infusion (sterile concentrate). The concentrate is colorless to slightly yellow and should not contain visible particles. It is provided in a transparent glass vial with a rubber stopper and an aluminum seal with a plastic cap.

Pack size: 1 vial of 5 ml

Marketing authorisation holder

Ultragenyx Germany GmbH

Rahel-Hirsch-Str. 10

10557 Berlin

Germany

Manufacturer

Ultragenyx Netherlands B. V.

Evert van de Beekstraat 1, Unit 104

1118 CL Schiphol

Netherlands

Millmount Healthcare Ltd.

Block-7, City North Business Campus

Stamullen, Co. Meath,

Ireland

You can request more information about this medicine from the local representative of the marketing authorisation holder:

BE, BG, CZ, DK, DE, EE, IE, EL, ES, HR, IT, CY, LV, LT, LU, HU, MT, NL, AT, PL, PT, RO, SI, SK, FI, SE, XI

Ultragenyx Germany GmbH, DE

Tel: + 49 30 20179810

FR

Ultragenyx France SAS, FR

Tel: + 33 185 653761 or 0800 91 79 24 (green number)

Date of last revision of this leaflet: MM/AAAA.

This medicine has been authorised under "exceptional circumstances". This means that due to the low prevalence of this disease, it has not been possible to obtain complete information on this medicine.

The European Medicines Agency will review any new information on this medicine that becomes available every year and this leaflet will be updated as necessary.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

------------------------------------------------------------------------------------------------------------------------

Online doctors for MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION

Discuss questions about MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (140)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

Camera Book a video appointment
€50
5.0 (29)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.
Camera Book a video appointment
€60

Frequently Asked Questions

Is a prescription required for MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION?
MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION?
The active ingredient in MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION is vestronidase alfa. This information helps identify medicines with the same composition but different brand names.
Who manufactures MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION?
MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION is manufactured by Ultragenyx Germany Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to MEPSEVII 2 mg/ml CONCENTRATE FOR INFUSION SOLUTION?
Other medicines with the same active substance (vestronidase alfa) include ALDURAZYME, 100 U/mL Concentrate for Infusion Solution, BRINEURA 150 MG SOLUTION FOR INFUSION, CEREZYME 400 units powder for concentrate for infusion solution. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media